Actively Recruiting
Ticagrelore Alone Post PCI
Led by Shiraz University of Medical Sciences · Updated on 2025-05-21
5400
Participants Needed
2
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in registry of professor Kojuri cardiology clinic
CONDITIONS
Official Title
Ticagrelore Alone Post PCI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female above 20 years of age undergoing PCI with a drug-eluting stent for chronic coronary syndrome
- Provided written informed consent approved by the ethics committee of Shiraz University of Medical Sciences
You will not qualify if you...
- Contraindication to aspirin, clopidogrel, ticagrelor, or study drugs (including hypersensitivity, moderate/severe liver disease, active bleeding, major surgery within 30 days)
- Atrial fibrillation or need for oral anticoagulant therapy
- Use of strong CYP3A inhibitors, narrow therapeutic index CYP3A substrates, or strong CYP3A inducers
- Females of child-bearing age not having a negative pregnancy test or not willing to use effective contraception
- Breastfeeding females at enrollment
- Unsuccessful PCI or PCI without optimal stent placement
- Anatomical SYNTAX score ≥23 prior to PCI
- Planned surgical intervention for cardiac or non-cardiac condition
- Previous PCI within last 6 months
- Current or past acute coronary syndrome within 12 months
- History of definite stent thrombosis
- Cardiac valve disease requiring invasive therapy
- Acute heart failure
- Active myocarditis
- Cardiomyopathy
- Patient on hemodialysis
- History of stroke or transient ischemic attack
- History of intracranial hemorrhage or increased bleeding risk intracranial pathology
- Hemoglobin less than 10 g/dL
- Peptic ulceration within last 3 months unless healed
- Other conditions increasing bleeding risk with ticagrelor
- Participation in another investigational drug or device trial
- Unlikely to comply with study procedures or complete follow-up
- Known drug or alcohol dependence within past 12 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Cardiology Ward Shiraz University of Medical Sciences
Shiraz, Fars, Iran, 51318
Actively Recruiting
2
professor Kojuroi cardiology clinic
Shiraz, Iran, 7134814336
Actively Recruiting
Research Team
J
javad UOM Kojuri, MD.MS
CONTACT
J
javad UOM Kojuri, MD.MS.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here